 |
|
 |
 |

Home > Company Index > Drugs > Drug Manufacturers - Other > Orphan Medical, Inc.
 |
Orphan Medical, Inc. |
 |
 |
 |
PROFILE |
 |
Orphan Medical must know how it feels to be all alone. The company acquires, develops, and markets drugs for inadequately treated or uncommon diseases, taking advantage of incentives offered under the Orphan Drug Act of 1983. The company's products are drugs of high medical value, which means they represent a significant improvement over previous treatments for the same conditions. Orphan Medical's efforts are concentrated primarily on pharmaceuticals in its three selected, strategic therapeutic markets: antidotes for poisonings (Antizol); oncology support (Busulfex); and sleep disorders (Xyrem). The company uses third parties to manufacture and distribute its products in the US and several foreign countries.
COMPETITION |
 |
Cephalon, Inc. (CEPH)
GlaxoSmithKline plc (GSK)
MGI PHARMA, Inc. (MOGN)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 11.20
1-Yr. Sales Growth: 72.3%
Employees: 60
Revenue per employee: $186,666.67
KEY PEOPLE |
 |
John Howell Bullion
CEO
Timothy G. McGrath
CFO
CONTACT INFO |
 |
13911 Ridgedale Dr., Ste. 250
Minnetonka, MN 55305
US
Phone: 952-513-6900
Fax: 952-541-9209
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |